Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
5.72Last Year’s EPS
2.58Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a strongly positive commercial and financial picture: exceptional revenue growth (+90% YoY), first full-year operating profitability, a robust cash position (+>$1B YoY), and an expanding patient base (≈19,000). Clinically, the positive Phase III ADAPT OCULUS ocular MG readout (p=0.012; mean improvement 4.04 vs 1.99) and recent seronegative data (with a PDUFA in May) materially expand VYVGART’s addressable market and support label expansion. The company also highlighted a deepening pipeline and strategic investments in next-generation FcRn assets. Offsetting factors include a low gross margin (~11%), significant OpEx and R&D spend (combined R&D+SG&A $2.7B; ~30% YoY increase), a failed ALS study that halts that program, regulatory requests increasing trial burden in Graves, and payer/timing uncertainties that could delay realization of some label expansion benefits. Overall, the positive commercial momentum, profitability milestone, and major clinical win for ocular MG outweigh the challenges and near-term risks.Company Guidance
Strong Revenue Growth and Scale
Product net sales of $1.3B in Q4 2025 and $4.2B for full year 2025, representing year-over-year growth of 90%. U.S. Q4 product sales were $1.1B, up 68% year-over-year. Company achieved its first year of annual operating profitability with operating profit of $367M in Q4 and $1.1B for the year, and profit of $533M in Q4 and $1.3B for the full year.
Robust Balance Sheet
Cash, cash equivalents and current financial assets of $4.4B at the end of Q4, representing more than a $1B increase over the year, providing strong capital to invest in commercial expansion and pipeline.
Positive Phase III ADAPT OCULUS Ocular MG Results
Study met primary endpoint (MGII patient‑reported ocular score) with VYVGART Hytrulo showing a mean improvement of 4.04 vs 1.99 for placebo at week 4 (p=0.012). Clear improvements observed in diplopia and ptosis, favorable tolerability and no new safety signals. Company plans to file an sBLA for ocular MG.
Continued MG & CIDP Commercial Momentum
Approximately 19,000 patients on treatment globally at year-end 2025. VYVGART is the fastest-growing and #1 prescribed biologic in MG: 6 out of 10 MG patients starting on a biologic start with VYVGART; 70% of VYVGART patients switched from orals. Prefilled syringe (PFS) launch is a key driver of patient adoption and contributed to >4,700 prescribers (including a dozen new prescribers since PFS launch).
Access Wins Supporting Uptake
Important access win: UnitedHealthcare coverage for the prefilled syringe expanded covered lives to >90%, improving payer access for a key delivery format and supporting adoption in CIDP and MG.
Pipeline Depth and Next-Generation Programs
Advanced immunology pipeline including 4 new molecules from the IIP and next-generation FcRn assets ARGX-213 and ARGX-124. First-in-class candidates progressing (ARGX-121 targeting IgA, ARGX-118 targeting Galectin-10). Company expects to progress 3 Phase I programs in 2026 and has upcoming key readouts including empasiprubart (MMN) readout planned for Q4.
Operational and Strategic Execution
Delivered FY25 combined R&D and SG&A of $2.7B in line with guidance. Management outlines clear strategic priorities (Vision 2030) including label expansions (seronegative PDUFA May 10), new delivery modalities (auto-injector planned for 2027), and a disciplined indication expansion playbook.
Financial Discipline and Tax Position
Year-to-date gross margin ~11% with cost of sales $150M in Q4. Tax for Q4 and full year reflected a net benefit due to nonrecurring items and FX; company expects an effective tax rate in the low- to mid-teens going forward.
ARGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARGX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $816.95 | $771.53 | -5.56% |
Oct 30, 2025 | $821.97 | $820.36 | -0.20% |
Jul 31, 2025 | $598.89 | $670.33 | +11.93% |
May 08, 2025 | $622.93 | $569.12 | -8.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Argenx Se (ARGX) report earnings?
Argenx Se (ARGX) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Argenx Se (ARGX) earnings time?
Argenx Se (ARGX) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARGX EPS forecast?
ARGX EPS forecast for the fiscal quarter 2026 (Q1) is 5.72.